[ { "@graph" : [ { "@id" : "http://purl.org/np/RAhdJT3HLf7q4nrdriMV5f3LR_Nqi3EfF3AL53F_aOySE", "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ], "http://www.nanopub.org/nschema#hasAssertion" : [ { "@id" : "http://purl.org/np/RAhdJT3HLf7q4nrdriMV5f3LR_Nqi3EfF3AL53F_aOySE#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance" : [ { "@id" : "http://purl.org/np/RAhdJT3HLf7q4nrdriMV5f3LR_Nqi3EfF3AL53F_aOySE#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo" : [ { "@id" : "http://purl.org/np/RAhdJT3HLf7q4nrdriMV5f3LR_Nqi3EfF3AL53F_aOySE#pubinfo" } ] } ], "@id" : "http://purl.org/np/RAhdJT3HLf7q4nrdriMV5f3LR_Nqi3EfF3AL53F_aOySE#Head" }, { "@graph" : [ { "@id" : "http://purl.obolibrary.org/obo/DOID_9965", "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id" : "http://purl.org/np/RAhdJT3HLf7q4nrdriMV5f3LR_Nqi3EfF3AL53F_aOySE#association", "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ { "@id" : "http://purl.obolibrary.org/obo/DOID_9965" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ { "@id" : "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ { "@id" : "https://identifiers.org/drugbank:DB00359" } ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "sulfadiazine tablets usp are indicated in the following conditions chancroid trachoma inclusion conjunctivitis nocardiosis urinary tract infections primarily pyelonephritis pyelitis and cystitis in the absence of obstructive uropathy or foreign bodies when these infections are caused by susceptible strains of the following organisms escherichia coli klebsiella enterobacter staphylococcus aureus proteus mirabilis p vulgaris toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome as adjunctive therapy with pyrimethamine malaria due to chloroquine resistant strains of plasmodium falciparum prophylaxis of meningococcal meningitis when sulfonamide sensitive group a strains are known to prevail in family groups or larger closed populations the prophylactic usefulness of sulfonamides when group b or c infections are prevalent is not proved and may be harmful in closed population groups meningococcal meningitis when the organism has been demonstrated to be susceptible acute otitis media due to haemophilus influenzae prophylaxis against recurrences of rheumatic fever as an alternative to penicillin h influenzae important notes in vitro currently the increasing frequency of resistant organisms limits the usefulness of antibacterial agents including the sulfonamides especially in the treatment of recurrent and complicated urinary tract infections wide variation in blood levels may result with identical doses blood levels should be measured in patients receiving sulfonamides for serious infections free sulfonamide blood levels of 5 mg to 15 mg per 1 ml may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 1 ml may be considered optimal for serious infections twenty mg per 1 ml should be the maximum total sulfonamide level since adverse reactions occur more frequently above this level" } ], "https://w3id.org/biolink/vocab/association_type" : [ { "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation" } ], "https://w3id.org/biolink/vocab/provided_by" : [ { "@id" : "https://w3id.org/um/NeuroDKG" } ], "https://w3id.org/biolink/vocab/relation" : [ { "@id" : "https://schema.org/TreatmentIndication" } ] }, { "@id" : "https://identifiers.org/drugbank:DB00359", "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Drug" } ] } ], "@id" : "http://purl.org/np/RAhdJT3HLf7q4nrdriMV5f3LR_Nqi3EfF3AL53F_aOySE#assertion" }, { "@graph" : [ { "@id" : "http://purl.org/np/RAhdJT3HLf7q4nrdriMV5f3LR_Nqi3EfF3AL53F_aOySE#assertion", "http://www.w3.org/ns/prov#wasAttributedTo" : [ { "@id" : "https://orcid.org/0000-0002-1468-3557" } ] } ], "@id" : "http://purl.org/np/RAhdJT3HLf7q4nrdriMV5f3LR_Nqi3EfF3AL53F_aOySE#provenance" }, { "@graph" : [ { "@id" : "http://purl.org/np/RAhdJT3HLf7q4nrdriMV5f3LR_Nqi3EfF3AL53F_aOySE", "http://purl.org/dc/terms/created" : [ { "@type" : "http://www.w3.org/2001/XMLSchema#dateTime", "@value" : "2021-06-13T16:07:13.690+02:00" } ], "http://purl.org/dc/terms/creator" : [ { "@id" : "https://orcid.org/0000-0002-1468-3557" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ { "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ { "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ { "@id" : "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs" } ] }, { "@id" : "http://purl.org/np/RAhdJT3HLf7q4nrdriMV5f3LR_Nqi3EfF3AL53F_aOySE#sig", "http://purl.org/nanopub/x/hasAlgorithm" : [ { "@value" : "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey" : [ { "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature" : [ { "@value" : "SJB46rp4eMlqKFuZX3CLIUk/UFibIHVQgfT5C4aXoe9zZ00ENwgRRJjDqUGzaola9fiIRNrwNCpZhMMNfH3LArz3/IPW/W2uLGZrAMUha6ARHzvz0r/xTipYGGGexO55nBWinVvgfF3ao9r6zoOeAXWLsgkP1DbvoNctLzLxtU0=" } ], "http://purl.org/nanopub/x/hasSignatureTarget" : [ { "@id" : "http://purl.org/np/RAhdJT3HLf7q4nrdriMV5f3LR_Nqi3EfF3AL53F_aOySE" } ] } ], "@id" : "http://purl.org/np/RAhdJT3HLf7q4nrdriMV5f3LR_Nqi3EfF3AL53F_aOySE#pubinfo" } ]